TNFSF11 and sarcopenia: Research has shown that RANKL inhibition improves muscle strength and insulin sensitivity in osteoporotic mice and humans through the RANK/RANKL/OPG signaling pathways, potentially representing a new therapeutic avenue for sarcopenia [127].